https://www.selleckchem.com/products/ms4078.html
In this population, there was an 81% increase in the risk of mortality among patients who received HCQ at any time during their hospital stay versus no HCQ exposure (OR 1.81, 95% CI 1.20-2.77, p = 0.01). In this retrospective analysis, we found that there was no benefit of administration of HCQ on mortality in COVID-19 patients. These results support recent changes to clinical trials that discourage the use of HCQ in COVID-19 patients. In this retrospective analysis, we found that there was no benefit of administration of HCQ on mortalit
Like
Comment
Share
